Omeros Corporation
OMER
Positions held
Your positionsOMER isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Omeros Corporation is well-positioned in the biotechnology sector, focusing on innovative therapies that address significant unmet medical needs, which can lead to strong competitive advantages.
- Revenue increased by 188% compared to the prior quarter, reaching $29 million.
- Gross margin improved to 97.2%, up from 94.1% in the previous quarter.
- Despite recent revenue growth, Omeros has faced significant operating losses, indicating potential challenges in achieving sustainable profitability.
- The company reported a net income loss of $117.813 million in 2023.
- Operating margin remains low, with a recent expansion to only 0.3%.
Fundamentals
| Market cap | $1.38B | Enterprise value | $1.55B | Trailing P/E | 15.67 | Forward P/E | 15.54 |
| PEG | 0.81 | Price / book | -26.85 | Beta | 2.57 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 38.3% | Operating margin | 0.3% |
| Profit margin | 3.2% | ROE | — | ROA | -18.7% | Debt / equity | — |
| Current ratio | 1.95 | Free cash flow | $183.31M | Analyst recommendation | none | Mean target | $27.50 |
| 52w high | $21.24 | 52w low | $4.06 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $28.5M | $9.9M | $0.0M | $0.0M | $0.0M | — |
| Op margin | 0.3% | -176.1% | — | — | — | — |
| Net income | $13.2M | $56.1M | $86.5M | -$30.9M | -$25.4M | — |
| Gross margin | 97.2% | 94.1% | — | — | — | — |
| Gross profit | $27.7M | $9.3M | — | — | $0.0M | $0.0M |
| Operating income | $0.1M | -$17.4M | -$29.1M | -$26.4M | -$32.4M | — |
- Revenue +188% vs prior quarter ($29M vs $9.9M).
- Gross margin 97.2% (was 94.1% prior quarter).
- Operating margin expanded to 0.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$3.4M | -$157M | -$118M | $47.4M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | $0.0M |
| Operating income | -$123M | -$167M | -$165M | -$163M | — |
Headlines — positive tone
• [OK · fundamentals] Omeros Shares Rise After Cantor Fitzgerald Upgrade
News
2026-09-23 · Dow Jones Futures Fall After Nasdaq Hits New High; Sandisk, Micron Trigger Buy Signals
2026-09-22 · Top Midday Gainers
2026-09-22 · Omeros Shares Rise After Cantor Fitzgerald Upgrade
2026-09-22 · NTRA Stock Hits All-Time High, OMER Stock Scales 5-Year Peak – What’s Driving Investors’ Enthusiasm Today?
2026-09-01 · Omeros Insider Sold Shares Worth $929,668, According to a Recent SEC Filing
2026-08-28 · Omeros Insider Sold Shares Worth $282,094, According to a Recent SEC Filing
2026-08-28 · What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?
2026-08-25 · Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?
2026-08-21 · Omeros Insider Sold Shares Worth $276,773, According to a Recent SEC Filing
2026-08-20 · Omeros (OMER) Q2 2026 Earnings Call Transcript
2026-08-14 · Omeros (OMER) Turns Profitable As Investors Ask If The Repricing Has Gone Too Far
2026-08-13 · This Biotech Stock Just Gapped Up To A Five-Year High; Here's Why
Price (daily)
Full chart · RSI · MACD · patterns